Guo J, Cao Y, Wu QY, Cen LS. Potential mechanism of teneligliptin in the treatment of diabetic cardiomyopathy. World J Diabetes 2024; 15(10): 2002-2005 [PMID: 39493566 DOI: 10.4239/wjd.v15.i10.2002]
Corresponding Author of This Article
Lu-Sha Cen, PhD, Attending Doctor, Department of Ophthalmology, The First Affiliated Hospital of Zhejiang Chinese Medical University, No. 54 Youdian Road, Hangzhou 310006, Zhejiang Province, China. cenlusa2@sina.com
Research Domain of This Article
Research & Experimental Medicine
Article-Type of This Article
Editorial
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Diabetes. Oct 15, 2024; 15(10): 2002-2005 Published online Oct 15, 2024. doi: 10.4239/wjd.v15.i10.2002
Potential mechanism of teneligliptin in the treatment of diabetic cardiomyopathy
Jing Guo, Yi Cao, Qing-Yuan Wu, Lu-Sha Cen
Jing Guo, Yi Cao, Department of Dermatology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou 310006, Zhejiang Province, China
Qing-Yuan Wu, Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou 310006, Zhejiang Province, China
Lu-Sha Cen, Department of Ophthalmology, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou 310006, Zhejiang Province, China
Author contributions: Guo J and Wu QY designed and wrote the manuscript; Cao Y and Cen LS supervised the guidance of the manuscript; All authors have read and approved the final manuscript.
Supported byScientific Research Project Foundation of Zhejiang Chinese Medical University, No. 2023FSYYZZ01; and National Natural Science Foundation of China, No. 82104862.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Lu-Sha Cen, PhD, Attending Doctor, Department of Ophthalmology, The First Affiliated Hospital of Zhejiang Chinese Medical University, No. 54 Youdian Road, Hangzhou 310006, Zhejiang Province, China. cenlusa2@sina.com
Received: March 28, 2024 Revised: July 6, 2024 Accepted: July 15, 2024 Published online: October 15, 2024 Processing time: 182 Days and 5.5 Hours
Abstract
Diabetic cardiomyopathy (DCM), a complication of diabetes, poses a significant threat to public health, both its diagnosis and treatment presents challenges. Teneligliptin has promising applications and research implications in the treatment of diabetes mellitus. Zhang et al observed the therapeutic effect of teneligliptin on cardiac function in mice with DCM. They validated that teneligliptin’s mechanism of action in treating DCM involves cardiomyocyte protection and inhibition of NLRP3 inflammasome activity. Given that the NLRP3 inflammasome plays a crucial role in the onset and progression of DCM, it presents a promising therapeutic target. Nevertheless, further clinical validation is required to ascertain the preventive and therapeutic efficacy of teneligliptin in DCM.
Core Tip: Diabetic cardiomyopathy (DCM) is a complication of diabetes, presenting significant challenges in both diagnosis and treatment of DCM. Zhang et al observed the therapeutic effect of teneligliptin on cardiac function in mice with DCM. They confirmed that teneligliptin functions by protecting cardiomyocytes and mitigating inflammation by inhibiting NLRP3 inflammasome activity. This discovery offers clinical management of DCM patients; however, its clinical application necessitates further clinical verification and discussion.
